Issue release date: 30.01.2026
2Bezmialem Vakif University, Beykoz Institute of Life Sciences and Biotechnology, Department of Molecular Biology, Istanbul, Türkiye
3College of Medicine University of Nebraska Medical Center, Department of Biochemistry and Molecular Biology, Nebraska, USA
4Bezmialem Vakif University Faculty of Medicine, Department of Neurosurgery, Istanbul, Türkiye DOI : 10.5137/1019-5149.JTN.46743-24.3 AIM: To evaluate the diagnostic potential of c-MYC, FABP7, GATA4, and MAOB in meningioma patients by analyzing their expression in serum samples.
MATERIAL and METHODS: The study included 20 patients who underwent surgical resection for intracranial meningiomas. Tumor and serum samples were collected during the surgical procedure. Real-time polymerase chain reaction (RT-PCR) was performed to measure the expression of FABP7, GATA4, c-MYC, and MAOB in both tumor tissues and serum samples.
RESULTS: The expression levels of MAOB, c-MYC, and GATA4 were significantly higher in grade 2 meningioma tumor tissues compared to grade 1 tumors (p=0.031, p=0.041, and p=0.003, respectively). Similarly, patients with grade 2 meningiomas had significantly higher MAOB expression in their serum compared to patients with grade 1 meningiomas (p=0.032). In addition, the serum levels of FABP7 and MAOB were significantly higher in meningioma patients compared to healthy controls (p<0.05).
CONCLUSION: The findings of this study suggest that FABP7 and MAOB expression in serum may serve as diagnostic markers for meningiomas. However, additional studies with larger cohorts are necessary to validate these results.
Keywords : Meningioma, Cancer biomarker, Liquid biopsy, Diagnosis